Literature DB >> 19107816

Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells.

Sri Balasubashini Muralimanoharan1, A B Kunnumakkara, Bhaskaran Shylesh, Kaustubh H Kulkarni, Xu Haiyan, Hu Ming, Bharat B Aggarwal, Ghosh Rita, Addanki P Kumar.   

Abstract

BACKGROUND: Epidemiological and laboratory studies support the hypothesis that several plant components influence prostate carcinogenesis and holds promise for disease prevention. Previously we reported that Nexrutine (bark extract from Phellodendron amurense) inhibits proliferation of prostate cancer cells and prostate tumor development in the transgenic adenocarcinoma of mouse prostate (TRAMP) model through modulation of Akt signaling pathway. In the present investigation we conducted studies to further define the mechanism of action of Nexrutine and to identify the active component associated with its biological activity.
METHODS: Androgen-responsive, androgen-independent human prostate cancer cell lines and tissues from TRAMP mice fed Nexrutine(R) were used in these studies. Activity guided fractionation identified butanol fraction recapitulating the activities of Nexrutine assessed by proliferation assays, apoptotic assays (DAPI and TUNEL staining), transient transfections, gel shift assays and Western blotting. In addition ultra-performance liquid chromatography (UPLC) of butanol fraction was used to identify active component of Nexrutine.
RESULTS: Butanol fraction recapitulated the activities of Nexrutine in (i) inhibiting proliferation; (ii) inducing apoptosis; and (iii) modulating transcriptional activity of NFkappaB in prostate cancer cells. Our data also indicates that both Nexrutine and butanol fraction modulates NFkappaB transcriptional activity by inhibiting IkappaBalpha phosphorylation. Expression of p65 and phosphorylated IkappaBalpha are high in tumors from TRAMP mice. In contrast dietary administration of Nexrutine reduced expression of p65 and phosphorylated IkappaBalpha in prostate from TRAMP mice. In addition using UPLC, we have identified berberine or closely related compound in the butanol fraction.
CONCLUSION: The results suggest that berberine or closely related component of butanol fraction may be responsible for the observed biological activities and induce apoptosis in prostate cancer cells by targeting critical cell survival signaling pathways both in vitro and in vivo. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19107816      PMCID: PMC2674392          DOI: 10.1002/pros.20899

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  35 in total

Review 1.  Hormone refractory prostate cancer.

Authors:  E D Crawford; M Rosenblum; A M Ziada; P H Lange
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

2.  Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.

Authors:  Eiji Kikuchi; Yutaka Horiguchi; Jun Nakashima; Kenji Kuroda; Mototsugu Oya; Takashi Ohigashi; Nozomu Takahashi; Yutaka Shima; Kazuo Umezawa; Masaru Murai
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

3.  Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines.

Authors:  A Mukhopadhyay; C Bueso-Ramos; D Chatterjee; P Pantazis; B B Aggarwal
Journal:  Oncogene       Date:  2001-11-15       Impact factor: 9.867

4.  2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells.

Authors:  A P Kumar; G E Garcia; T J Slaga
Journal:  Mol Carcinog       Date:  2001-07       Impact factor: 4.784

5.  4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management.

Authors:  Addanki P Kumar; Gretchen E Garcia; Rita Ghosh; Rajendran V Rajnarayanan; William L Alworth; Thomas J Slaga
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

6.  Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation.

Authors:  Syed M Meeran; Suchitra Katiyar; Santosh K Katiyar
Journal:  Toxicol Appl Pharmacol       Date:  2008-01-17       Impact factor: 4.219

7.  JFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cells.

Authors:  Sergio D Catz; Bernard M Babior; Jennifer L Johnson
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

Review 8.  The Akt pathway: molecular targets for anti-cancer drug development.

Authors:  Constantine S Mitsiades; Nicholas Mitsiades; Michael Koutsilieris
Journal:  Curr Cancer Drug Targets       Date:  2004-05       Impact factor: 3.428

9.  Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway.

Authors:  Yiwei Li; Fazlul H Sarkar
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

10.  Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells.

Authors:  Junghan Suh; Faribourz Payvandi; Leonard C Edelstein; Peter S Amenta; Wei-Xing Zong; Céline Gélinas; Arnold B Rabson
Journal:  Prostate       Date:  2002-08-01       Impact factor: 4.104

View more
  19 in total

1.  Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP.

Authors:  Heather G Hambright; Izhar Singh Batth; Jianping Xie; Rita Ghosh; Addanki Pratap Kumar
Journal:  Mol Carcinog       Date:  2014-07-07       Impact factor: 4.784

2.  Dietary administration of berberine or Phellodendron amurense extract inhibits cell cycle progression and lung tumorigenesis.

Authors:  Michael A James; Huijing Fu; Yan Liu; Da-Ren Chen; Ming You
Journal:  Mol Carcinog       Date:  2011-01       Impact factor: 4.784

Review 3.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

4.  Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.

Authors:  Jingjing Gong; Amanda R Muñoz; Subramanya Pingali; Florastina Payton-Stewart; Daniel E Chan; James W Freeman; Rita Ghosh; Addanki P Kumar
Journal:  Mol Carcinog       Date:  2016-05-25       Impact factor: 4.784

5.  Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress.

Authors:  Guo-long Zhao; Li-ming Yu; Wen-li Gao; Wei-xun Duan; Bo Jiang; Xu-dong Liu; Bin Zhang; Zhen-hua Liu; Meng-en Zhai; Zhen-xiao Jin; Shi-qiang Yu; Yun Wang
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

6.  Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer.

Authors:  Gregory P Swanson; William E Jones; Chul S Ha; Carol A Jenkins; Addanki Pratap Kumar; Joseph Basler
Journal:  Phytother Res       Date:  2014-09-09       Impact factor: 5.878

7.  Extracting the Benefit of Nexrutine® for Cancer Prevention.

Authors:  Suleman S Hussain; Darpan Patel; Rita Ghosh; Addanki P Kumar
Journal:  Curr Pharmacol Rep       Date:  2015-03-21

8.  Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells.

Authors:  Heather G Hambright; Peng Meng; Addanki P Kumar; Rita Ghosh
Journal:  Oncotarget       Date:  2015-03-30

9.  Cytotoxic Effect of Coscinium fenestratum on Human Head and Neck Cancer Cell Line (HN31).

Authors:  Saranyapin Potikanond; Natthakarn Chiranthanut; Parirat Khonsung; Supanimit Teekachunhatean
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

10.  Transportation of berberine into HepG2, HeLa and SY5Y cells: a correlation to its anti-cancer effect.

Authors:  Yu-Nong Pang; Yin-Wen Liang; Tian-Shi Feng; Shuang Zhao; Hao Wu; Yu-Shuang Chai; Fan Lei; Yi Ding; Dong-Ming Xing; Li-Jun Du
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.